Prelude Therapeutics announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC. The Company also announced the appointment of two new members to its Board of Directors: Mardi C. Dier: Ms. Dier most recently served as Executive Vice President, Chief Financial Officer and Chief Business Officer of Portola Pharmaceuticals Inc. prior to its acquisition by Alexion Pharmaceuticals in July 2020. Victor Sandor, M.D.: Dr. Sandor was most recently Chief Medical Officer at Array BioPharma Inc. prior to its acquisition by Pfizer Inc.